The IPXL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IPXL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The IPXL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View IPXL Detailed Price Forecast - CNN Money||View IPXL Detailed Summary - Google Finance|
|View IPXL Detailed Summary - Yahoo! Finance||View IPXL Stock Research & Analysis - Zacks.com|
|View IPXL Trends & Analysis - Trade-Ideas||View IPXL Major Holders - Barrons|
|View IPXL Call Transcripts - NASDAQ||View IPXL Breaking News & Analysis - Seeking Alpha|
|View IPXL Annual Report - CompanySpotlight.com||View IPXL OTC Short Report - OTCShortReport.com|
|View IPXL Fundamentals - TradeKing||View IPXL SEC Filings - Bar Chart|
|View Historical Prices for IPXL - The WSJ||View Performance/Total Return for IPXL - Morningstar|
|View the Analyst Estimates for IPXL - MarketWatch||View the Earnings History for IPXL - CNBC|
|View the IPXL Earnings - StockMarketWatch||View IPXL Buy or Sell Recommendations - MacroAxis|
|View the IPXL Bullish Patterns - American Bulls||View IPXL Short Pain Metrics - ShortPainBot.com|
|View IPXL Stock Mentions - StockTwits||View IPXL Stock Mentions - PennyStockTweets|
|View IPXL Stock Mentions - Twitter||View IPXL Investment Forum News - Investor Hub|
|View IPXL Stock Mentions - Yahoo! Message Board||View IPXL Stock Mentions - Seeking Alpha|
|View Insider Transactions for IPXL - SECform4.com||View Insider Transactions for IPXL - Insider Cow|
|View IPXL Major Holdings Summary - CNBC||View Insider Disclosure for IPXL - OTC Markets|
|View Insider Transactions for IPXL - Yahoo! Finance||View Institutional Holdings for IPXL - NASDAQ|
|View IPXL Stock Insight & Charts - FinViz.com||View IPXL Investment Charts - StockCharts.com|
|View IPXL Stock Overview & Charts - BarChart||View IPXL User Generated Charts - Trading View|
Impax Announces the Launch of an Authorized Generic Version of Solodyn® (Minocycline HCl) Extended-Release Tablets
Posted on Tuesday February 20, 2018
Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments.
Lee Ainslie Boosts 2 Health Care Positions
Posted on Monday February 12, 2018
The guru added to his Envision Healthcare and Impax Laboratories holdings
Andrew S. Boyer Joins Amneal Pharmaceuticals as Executive Vice President, Commercial Operations
Posted on Tuesday February 06, 2018
BRIDGEWATER, N.J., Feb. 6, 2018 /PRNewswire/ -- Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (IPXL), today announced that Andrew S. Boyer, 52, has joined Amneal as Executive Vice President, Commercial Operations and is expected to serve in the same capacity for the new combined company following the consummation of the combination with Impax. "We are pleased that Andy has joined Amneal and will be leading our commercial organization," said Chirag Patel, Co-CEO and chairman, Amneal Pharmaceuticals. Mr. Boyer will work closely with Chirag and Chintu Patel, Amneal's current Co-CEOs, and Rob Stewart, President of Amneal and the future CEO of the new Amneal, to further enhance its business in preparation for the pending combination with Impax, which is currently expected to occur in the first half of 2018.
Amneal Launches Methylphenidate Hydrochloride Extended-Release Tablets, USP (CII) AB-Rated Generic for Concerta®
Posted on Monday February 05, 2018
BRIDGEWATER, N.J. , Feb. 5, 2018 /PRNewswire/ -- Amneal Pharmaceuticals has launched methylphenidate hydrochloride extended-release tablets, USP (CII) in 18, 27, 36, and 54 mg strengths. Amneal's methylphenidate ...